实体瘤的综合分子检测.pdf

1、Comprehensive Molecular Testing for Solid TumorsCaris Life SciencesBrian Liu,PhD.Whole Exome,Whole Transcriptome-Better StoryWES/WTS captures every detail,not just known biomarkersSLIDE DIMENSIONS SHOULD FOLLOW 16:9 RATIOComprehensive Molecular ProfilingReal-world evidence provides clinical insights

2、 into tissue-agnostic therapeutic approvalsPatient and Specimen InformationResults with Therapy AssociationsImportant Note Contains significant information about drug/biomarker associations and comments from Caris pathologists and/or molecular geneticists,if applicableCancer-type Relevant Biomarkers

3、shows key biomarker results,list adapts by tumor typeTherapeutic associations continuously updated based on:FDA approvals Industry guidelines Literature Physician feedbackAlso included in the report:Molecular signatures Clinical trials Specimen information Methods&detailed testing results CitationsP

4、atient and Specimen InformationResults with Therapy AssociationsContains drug associations ranked by level of evidence:Level 1=Biomarker test noted in FDA indicationLevel 2=Endorsed by clinical guidelinesLevel 3=Evidence exists in patients tumor typeTumor Associated Findingssomatic mutations and mol

5、ecular signatures are noted.Incidental Findingsincluding incidental germline*and incidental CH variants are distinguished from somatic tumor variants.Therapeutic associations are constantly updated based on:FDA approvals Industry guidelines Literature Physician feedbackhttps:/ signaling has a pivota

6、l role in kidney cancer.Promotes crucial pathological processes such as hypoxia-inducible factor(HIF)activation.Angiogenesis Proliferation Metabolic reprogramming Drug resistanceA substantial portion of ccRCC is characterized by a loss of V